FDA-approved Spravato®: A safer standard.
Ketamine is a well-researched, regulated, and 100% legal medication when properly administered. At Marpa Minds, we go one step further, reaching for the only version of ketamine that’s actually approved by the FDA for depression: Esketamine, known as Spravato®, a nasal spray that’s patented, highly studied, and covered by insurance.
While ketamine clinics typically offer ketamine in IV form, Spravato®’s inhaled solution is far gentler and better-tolerated by most people. Fewer negative experiences means more positive ones!
Compared to traditional antidepressants
Easy to administer
Nasal spray is more user-friendly than IV infusions
Fewer side effects
Side effects rarely last past 2 hour treatment window
Of Marpa patients report a noticeable reduction in depressive symptoms within 24 hours of their first Spravato treatment.
# sessions are recommended for most patients to experience a significant decline in depressive symptoms.
Of patients might experience transient side effects like dizziness or disassociation, which generally abate before leaving the treatment facility.
Are you eligible for Spravato?
Spravato is developed to treat for TRD, or treatment-resistant depression. Learn if it’s right for you.
You’ve been diagnosed with depression
You have tried at least 2 forms of medication
The medication has not successfully alleviated your depressive symptoms
The Minds at Marpa
Our team is made up of doctors, and clinicians across the field of mental health and cutting-edge psychedelic research.
Dr. Ben Medrano
Dr. Ben Medrano
Dr. Ben Medrano is a board certified psychiatrist specializing in Integrative Psychiatry, Ketamine Assisted Therapy and Psychedelic Harm Reduction and Integration. He received his MD from the University of Colorado School of Medicine with additional training in their Urban Underserved Track. He completed his psychiatric residency training within the Mount Sinai Hospital system in New York City and spent years working for the urban underserved particularly in East Harlem Assertive Community Treatment performing daily home visits for high risk consumers before focusing on the use of psychedelics in mental health.
He’s a graduated fellow in Integrative Psychiatry through the Integrative Psychiatry Institute’s Fellowship where he also received additional training through their Ketamine for Medical Providers program with sponsorship and certification from the American Society of Ketamine Physicians. He has trained with numerous leaders in the field of ketamine assisted therapy, including Phil Wolfson, MD and has joined him in leading clinician education at The Ketamine Training Center.
His clinical practice has been strongly influenced by an ongoing interest in consciousness, psychedelics, and integrative medicine. He is a graduate of Vajrayana Buddhist seminary and is a rigorously trained meditation instructor with over 20 years of ongoing intensive training. He continues to study psychedelic therapy modalities within the community of senior students of Ralph Metzner, PhD who was a leader in the field of consciousness expanding therapies.
Dr. Medrano is most known for his work with ketamine assisted therapy and was the national Medical Director of Field Trip Health – one of the largest in-office ketamine assisted therapy practices to date. Following this he served as Chief Medical Officer at Nue.Life a large scale home-based ketamine assisted therapy and integrative mental health provider.
In addition to multiple conference speaking engagements, he lectures on the utility of ketamine and psychedelics for mental health at Naropa University. He currently serves on the HealingMaps.com Medical Advisory. His work, insight and advice have been covered in a number of articles including The New York Times, The New Yorker, Forbes, Business Insider, The New York Post, Cheddar, Bloomberg, The Houston Chronicle, HealthLine, VeryWellMind, YahooFinance, The Dales Report, The Zoe Report, and numerous others.
Dr. Medrano is the Practice Owner and serves as the Medical Director of the Marpa Mind’s Spravato Treatment Centers.
Rivka is the Director of Marpa Minds, and she considers herself incredibly fortunate to operate at the convergence of three areas she deeply cares about and holds extensive experience in: Psychedelics, Mental Health, and Business Operations. Her mission is to leverage her operational expertise to ensure this transformative space delivers the care it promises. She is dedicated to delivering the system that empowers medical professionals to excel in their roles: delivering exceptional care and unwavering patient support. Together, Rivka and her team are poised to make a meaningful impact in the field of mental health.
Christy serves as an intuitive guide at Marpa Minds, acting as a reflective mirror to the unique experiences of each individual. As an unbiased witness, she assists clients on their profound journey towards self-discovery and realization. At the core of her approach is the goal of helping clients remember — remember their true essence, their soul’s purpose, the inherent beauty that encompasses our existence, and the innate wisdom that dwells within.
Dedicated to fostering growth, Christy is committed to holding clients accountable for their personal and spiritual evolution. With her guidance, clients navigate challenges, unveiling the hidden lessons they present. Together, they embark on a transformative process to cultivate self-love, peace, and a harmonious alignment of body, mind, and spirit.
Educator for Psilocybin Facilitators
Educator for Psilocybin Facilitators
Samantha is honored to collaborate with the team at Marpa Minds to assist in the integration of traditional holistic healing modalities into psychedelic treatment. Samantha currently maintains a private spiritual healing practice based in Manhattan. Her healing lineage training has been passed through traditional apprenticeship from her teacher Ron Young (The Wisdom of Healing School). Her meditation and spiritual development are rooted in yoga and Vedanta lineages. Samantha is trained in interfaith spiritual care and chaplaincy through both the Graduate Theological Union at Berkeley and Emory University Spiritual Health. She has completed graduate training in Spiritual Psychology (Columbia University) and cognitive neuroscience (The University of Western Ontario). Samantha has worked in the field of psychedelic medicine at the NYU Center for Psychedelic Medicine for nearly a decade and is an educator for psilocybin facilitators at the Changa Institute in Oregon.
Amy Della Rocca
Amy Della Rocca
Meet Amy Della Rocca, a Psychiatric Nurse Practitioner who has delved into the realm of psychedelic medicine. Amy’s credentials hail from Columbia University and her previous work experience is in Behavioral Health, Public health and Primary Care Medicine.
Amy’s unwavering belief in the potential of ketamine treatment for mental well-being stems from hands-on experience with her patients. Witnessing its positive impact and lasting changes drove her to specialize in this unique field.
What sets Amy apart is her holistic approach. She considers medical, emotional, and psychological aspects, earning respect for her practical solutions.
Operating from Marpa, Amy evaluates patients for Spravato compatibility. She provides comprehensive on-site care during their Spravato treatment journey. Amy supports patients from evaluation to treatment completion and collaborates with their existing mental and physical health care team.
Amy’s contribution goes beyond caregiving; she actively advances psychedelic medicine. Her expertise and dedication have garnered trust among colleagues and patients alike.
Clinical Operations Manager
Clinical Operations Manager
Meet Alexandra Ortiz, Clinic Manager and Intake Coordinator at Marpa Minds. With a strong background in clinical psychology and health administration, Alexandra excels in foreseeing challenges and navigating complex regulations with poise and precision.
Her expertise in streamlining processes and ensuring smooth operations took root during her time at Field Trip Health & Wellness, where she contributed to launching multiple clinics and managing the New York City location from 2020 to 2023. Thriving in the fast-paced ketamine industry, Alexandra’s unwavering attention to detail and dedication to precision drive her to constantly push boundaries and discover innovative ways to improve clinic operations.
As a dedicated advocate for safe, affordable and effective solutions for mental health, Alexandra is proud to be part of Marpa Mind’s vision. Her leadership style is characterized by empathy and approachability, fostering a culture of inclusivity and respect within our clinical team and patients.
Her guiding principle is the well-being and safety of our clients. Alexandra ensures that every decision is rooted in ethical principles, driven by a commitment to positive impact towards our patients health and wellbeing.
With Marpa, a significant majority of clients experience an improvement in mood shortly after administration. — safely.
I felt like I was drowning. Marpaminds helped me find myself again.
- Tried Duloxetine, Citalopram and Sertraline
- Maintenance Marpa visits once a month
- Sees therapist once a week
Real Estate Attorney, Age 34
After the better part of a decade, I can finally feel again. It was Spravato!!
- Tried Duloxetine & Bupropion SR
- 11 Marpa clinic sessions total
- In remission from MDD for 6 months
Elementary School Teacher, Age 49
I would not be exaggerating to say that Marpaminds saved my life. Thank you.
- Tried Fluoxetine, Olanzapine, and ECT
- Maintenance Marpa visits every six weeks
- In remission from MDD for 6 months
Engineer, Age 46
Esketamine has significantly decreased my anxiety symptoms.
- Tried Sertraline, Lamotrigine, Desvenlafaxine, and rTMS
- 20 Marpaminds session total
- In remission from MDD for 1 year
Student, Age 22
Read the research
A growing body of clinical research shows that ketamine can successfully treat mental health symptoms. We’ve gathered it here so you can read it for yourself!
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)
What it’s about This study found that the combination therapy of Spravato nasal spray and an oral antidepressant in TRD was well-tolerated, and no new safety concerns were identified over the long-term treatment period.
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Anxiety in Patients With Treatment-Resistant MDD: A Retrospective Chart Review
What it’s about This chart review evaluated the efficacy and safety of intranasal esketamine (Spravato) in patients with treatment-resistant depression. The study found that intranasal esketamine was effective in rapidly reducing symptoms of depression and anxiety, and was well-tolerated.
Spravato (Esketamine Nasal Spray) for Treatment-Resistant Depression: A Review of Clinical Effectiveness and Cost-Effectiveness
What it’s about This review found that Spravato was effective in reducing depressive symptoms, but the cost-effectiveness was uncertain due to limited data.
Effects of repeated ketamine infusions on cognition: Systematic review and meta-analysis
What it’s about The study found that repeated ketamine infusions did not have a significant negative impact on cognitive function in patients with treatment-resistant depression.
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
What it’s about This study found that intranasal esketamine (Spravato) was effective in rapidly reducing symptoms of depression and suicidality in patients at imminent risk for suicide. The treatment was well-tolerated, and no new safety concerns were identified.
Esketamine Nasal Spray for the Management of Treatment-Resistant Depression: A Review of Current Evidence
What it’s about This review article summarizes the current evidence on the use of esketamine nasal spray for treatment-resistant depression. The authors conclude that esketamine appears to be an effective and well-tolerated treatment option for this population.
Esketamine Nasal Spray for Major Depressive Disorder: A Review of Safety and Efficacy
What it’s about This review article discusses the safety and efficacy of esketamine nasal spray for major depressive disorder. The authors conclude that the treatment is effective, with a rapid onset of action, and that the safety profile is generally favorable.
Esketamine Nasal Spray for the Treatment of Major Depressive Disorder: A Review of Clinical and Economic Evidence
What it’s about This review article discusses the clinical and economic evidence on the use of esketamine nasal spray for major depressive disorder. The authors conclude that the treatment is effective and provides a cost-effective option for patients who have not responded to other treatments.
Esketamine Nasal Spray for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients with Major Depressive Disorder and Bipolar Depression
What it’s about This study found that esketamine nasal spray was effective in rapidly reducing symptoms of depression and suicidality in patients with major depressive disorder and bipolar depression. The treatment was well-tolerated, and no new safety concerns were identified.